Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven major markets (7MM) of the United States, France, Germany, Italy, Spain, United Kingdom and Japan by the year end of 2022.
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against seasonal influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. The barriers limiting the growth of the influenza market include limited patient awareness regarding the threat of influenza and the importance of influenza vaccinations, high investment and strict regulations act as barriers for new entrants.
The United States seasonal influenza vaccine market is the most attractive of those covered in the report. The United States market for seasonal influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. United Kingdom will be the second–largest market for seasonal influenza vaccine which is expected to grow at a CAGR of XX% by 2022. Germany is expected to be third largest seasonal influenza vaccine market being followed by Japan by the end of the forecasted period.
Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the seasonal influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the seasonal influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into seasonal influenza vaccine sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in seasonal influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the seasonal influenza vaccine market such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook, and sales analysis of seasonal influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of seasonal influenza vaccine market.
Seven Major Markets(7MM) covered in the report are as follows:
1. United States
2. United Kingdom
3. France
4. Italy
5. Spain
6. Germany
7. Japan
Major and Promising Vaccines covered in the report are as follows:
1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4. Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8. FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax
Seasonal Influenza Vaccine Report is segmented with 10 Chapters:
Chapter 1: Chapter one is the introduction with Executive Summary
Chapter 2: Chapter two provides overall recent and forecasts data for the seasonal influenza vaccine market in the top seven countries. This Chapter divided into 4 parts
1. Overall seasonal influenza vaccine market data from 2010 to 2022
2. Overall number of persons vaccinated with seasonal influenza vaccine data from 2010 to 2022
3. Seasonal influenza vaccine market share in the top seven countries data from 2010 to 2022
4. Persons being vaccinated with influenza vaccine share in the top seven countries data from 2010 to 2022
Chapter 3: Key market drivers and barriers in the seasonal influenza vaccine market.
Chapter 4: Chapter four gives detailed recent and forecasts for the seasonal influenza vaccine markets in the US, the UK, France, Italy, Spain, Germany and Japan, comprising of market size, total number of persons vaccinated, number of children vaccinated, number of 60+ years of age persons vaccinated, number of pregnant women vaccinated, number of chronic medical condition persons vaccinated, number of healthcare workers vaccinated and vaccination coverage.
Chapter 5: Chapter five gives detailed information on seasonal influenza vaccine production & distribution in United States. The information includes vaccine choices remain available for patients, providers, prices of a dose of vaccine, production, supply, and allocation by the major seasonal influenza vaccine manufacturers, seasonal influenza vaccine distribution & demand, seasonal influenza vaccine effectiveness, managing influenza with diagnostic resources, distribution method of seasonal influenza vaccination.
Chapter 6: Chapter six offers information about regulatory landscape including the approval process and an overview of the regulatory authorities in the United States, EU and Japan.
Chapter 7: Chapter seven highlights key M&A deals that took place in the seasonal influenza vaccine market between 2003 and 2015 and lists the major collaborations, licensing, exclusive and distribution agreements deals.
Chapter 8: Chapter eight provides detailed pipeline influenza vaccines in various companies’ pipelines with clinical development and early stage development vaccines.
Chapter 9: Chapter nine offers detailed information of the recruiting clinical trials statement by phase, trial status, study sponsor name and study phase.
Chapter 10: Chapter ten gives information on the key players in the market with business overview, product outlook and sales analysis of the seasonal influenza vaccine.
Table of Contents
1. Executive Summary
2. Seasonal Influenza Vaccine Market in Top Seven Countries – Market Overview
2.1 Seasonal Influenza Vaccine Market
2.2 Number of Persons Vaccinated with Influenza Vaccine
2.3 Seasonal Influenza Vaccine Market Share
2.4 Persons Being Vaccinated with Influenza Vaccine Share
3. Seasonal Influenza Vaccine Market Drivers and Barriers
3.1 Market Drivers
3.2 Market Barriers
4. Seasonal Influenza Vaccine Market in Top Seven Countries – Geographical Landscape
4.1 United States
4.1.1 Seasonal Influenza Vaccine Market
4.1.2 Total – Number of Persons Vaccinated with Seasonal Influenza Vaccine
4.1.2.1 Number of Children Vaccinated
4.1.2.2 Number of Adults Vaccinated
4.2 Germany
4.2.1 Seasonal Influenza Vaccine Market
4.2.2 Total – Number of Persons Vaccinated with Seasonal Influenza Vaccine
4.2.2.1 Number of 60+ Years of Age Persons Vaccinated
4.2.2.2 Number of Pregnant Women Vaccinated
4.2.2.3 Number of Chronic Medical Condition Persons Vaccinated
4.2.2.4 Number of Healthcare Workers Vaccinated
4.3 France
4.3.1 Seasonal Influenza Vaccine Market
4.3.2 Total – Number of Persons Vaccinated with Seasonal Influenza Vaccine
4.3.2.1 Number of 65+ Years of Age Persons Vaccinated
4.3.2.2 Number of Pregnant Women Vaccinated
4.3.2.3 Number of Chronic Medical Condition Persons Vaccinated
4.3.2.4 Number of Healthcare Workers Vaccinated
4.4 Italy
4.4.1 Seasonal Influenza Vaccine Market
4.4.2 Total – Number of Persons Vaccinated with Seasonal Influenza Vaccine
4.4.2.1 Number of 65+ Years of Age Persons Vaccinated
4.4.2.2 Number of Pregnant Women Vaccinated
4.4.2.3 Number of Chronic Medical Condition Persons Vaccinated
4.4.2.4 Number of Healthcare Workers Vaccinated
4.5 United Kingdom
4.5.1 Seasonal Influenza Vaccine Market
4.5.2 Total – Number of Persons Vaccinated with Seasonal Influenza Vaccine
4.5.2.1 Number of Children Vaccinated
4.5.2.2 Number of 65+ Years of Age Persons Vaccinated
4.5.2.3 Number of Pregnant Women Vaccinated
4.5.2.4 Number of Chronic Medical Condition Persons Vaccinated
4.5.2.5 Number of Healthcare Workers Vaccinated
4.6 Spain
4.6.1 Seasonal Influenza Vaccine Market
4.6.2 Total – Number of Persons Vaccinated with Seasonal Influenza Vaccine
4.6.2.1 Number of 65+ Years of Age Persons Vaccinated
4.6.2.2 Number of Pregnant Women Vaccinated
4.6.2.3 Number of Chronic Medical Condition Persons Vaccinated
4.6.2.4 Number of Healthcare Workers Vaccinated
4.7 Japan
4.7.1 Seasonal Influenza Vaccine Market
4.7.2 Total – Number of Persons Vaccinated with Seasonal Influenza Vaccine
4.7.2.1 Number of Children Vaccinated
4.7.2.2 Number of 65+ Years of Age Persons Vaccinated
4.7.2.3 Number of Pregnant Women Vaccinated
4.7.2.4 Number of Chronic Medical Condition Persons Vaccinated
4.7.2.5 Number of Healthcare Workers Vaccinated
5. Seasonal Influenza Vaccine Production & Distribution in United States
5.1 Vaccine Choices Remain Available for Patients, Providers
5.2 Seasonal Influenza Vaccine Price Trends
5.2.1 Pediatric Seasonal Influenza Vaccine Price Trends
5.2.2 Adult Seasonal Influenza Vaccine Price Trends
5.3 Seasonal Influenza Vaccine Production, Supply, and Allocation
5.4 Seasonal Influenza Vaccine Distribution & Demand
5.5 Seasonal Influenza Vaccine Effectiveness
5.6 Managing Influenza with Diagnostic Resources
5.7 Distribution Method of Seasonal Influenza Vaccination
6. Seasonal Influenza Vaccine Market – Regulatory Landscape
6.1 Registration Process and Regulations for Vaccine in the US
6.2 Registration Process and Regulations for Vaccine in the EU
6.3 Registration Process and Regulations for Vaccine in Japan
7. Market Dynamics – Mergers, Acquisitions, Key Agreements & Collaborations
7.1 Merger & Acquisitions
7.2 Collaborations Deal
7.3 Licensing, Exclusive & Distribution Agreement Deal
7.3.1 Licensing Agreement
7.3.2 Exclusive Agreement
7.3.3 Distribution Agreement
8. Seasonal Influenza Vaccine – Pipeline Assessment
8.1 Promising Vaccine in Clinical Development
8.2 Promising Vaccine in Early–Stage Development
9. Seasonal Influenza Vaccine – Clinical Trials Assessment by Phase and Trial Status
9.1 Year 2016
9.2 Year 2015
9.3 Year 2014
9.4 Year 2013
10. Key Companies Analysis
10.1 Sanofi Pasteur
10.1.1 Business Overview
10.1.2 Sanofi Pasteur – Influenza Vaccine Outlook
10.1.2.1 Fluzone High–Dose Vaccine
10.1.2.2 Fluzone Quadrivalent Vaccine
10.1.2.3 Intradermal (ID) Trivalent Influenza Vaccine
10.1.2.4 Vaxigrip Vaccine
10.1.3 Seasonal Influenza Vaccine Sales Analysis
10.2 GlaxoSmithKline (GSK)
10.2.1 GlaxoSmithKline(GSK) – Influenza Vaccine Outlook
10.2.1.1 Fluarix Quadrivalent
10.2.1.2 Flulaval Quadrivalent
10.2.2 Seasonal Influenza Vaccine Sales Analysis & Forecast
10.3 AstraZeneca
10.3.1 Business Overview
10.3.2 AstraZeneca – Influenza Vaccine Outlook
10.3.2.1 Fluenz Tetra/FluMist Quadrivalent
10.3.3 Seasonal Influenza Vaccine Sales Analysis
10.4 Protein Sciences Corporation
10.4.1 Business Overview
10.4.2 Protein Sciences Corporation – Seasonal Influenza Vaccine Outlook
10.4.2.1 Flublok
10.5 Seqirus (CSL Limited)
10.5.1 Business Overview
10.5.2 Seqirus – Influenza Vaccine Outlook
10.5.2.1 Flucelvax Quadrivalent
10.5.2.2 Afluria Quadrivalent
10.5.2.3 Agrippal
10.5.2.4 Fluad
10.5.2.5 Fluvirin
10.5.2.6 Fluvax
